NeuroSense Therapeutics Statistics
Total Valuation
NRSN has a market cap or net worth of $28.59 million. The enterprise value is $27.58 million.
Important Dates
The last earnings date was Tuesday, March 31, 2026, before market open.
| Earnings Date | Mar 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NRSN has 35.35 million shares outstanding. The number of shares has increased by 36.98% in one year.
| Current Share Class | 35.35M |
| Shares Outstanding | 35.35M |
| Shares Change (YoY) | +36.98% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 26.36% |
| Owned by Institutions (%) | 1.02% |
| Float | 26.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 25.23 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.31
| Current Ratio | 0.31 |
| Quick Ratio | 0.08 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -2,174.98% and return on invested capital (ROIC) is -1,094.49%.
| Return on Equity (ROE) | -2,174.98% |
| Return on Assets (ROA) | -247.30% |
| Return on Invested Capital (ROIC) | -1,094.49% |
| Return on Capital Employed (ROCE) | 744.96% |
| Weighted Average Cost of Capital (WACC) | 13.40% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$654,412 |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.10% in the last 52 weeks. The beta is 1.68, so NRSN's price volatility has been higher than the market average.
| Beta (5Y) | 1.68 |
| 52-Week Price Change | -19.10% |
| 50-Day Moving Average | 0.80 |
| 200-Day Moving Average | 1.07 |
| Relative Strength Index (RSI) | 59.66 |
| Average Volume (20 Days) | 124,874 |
Short Selling Information
The latest short interest is 653,788, so 1.85% of the outstanding shares have been sold short.
| Short Interest | 653,788 |
| Short Previous Month | 594,593 |
| Short % of Shares Out | 1.85% |
| Short % of Float | 2.51% |
| Short Ratio (days to cover) | 3.50 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.09M |
| Pretax Income | -11.13M |
| Net Income | -11.13M |
| EBITDA | -11.07M |
| EBIT | -11.09M |
| Earnings Per Share (EPS) | -$0.44 |
Full Income Statement Balance Sheet
The company has $166,000 in cash and $170,000 in debt, with a net cash position of -$4,000 or -$0.00 per share.
| Cash & Cash Equivalents | 166,000 |
| Total Debt | 170,000 |
| Net Cash | -4,000 |
| Net Cash Per Share | -$0.00 |
| Equity (Book Value) | -1.56M |
| Book Value Per Share | -0.05 |
| Working Capital | -1.74M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$7.67 million and capital expenditures -$8,000, giving a free cash flow of -$7.68 million.
| Operating Cash Flow | -7.67M |
| Capital Expenditures | -8,000 |
| Depreciation & Amortization | 16,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.68M |
| FCF Per Share | -$0.22 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NRSN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -36.98% |
| Shareholder Yield | -36.98% |
| Earnings Yield | -40.35% |
| FCF Yield | -27.85% |
Analyst Forecast
The average price target for NRSN is $8.50, which is 950.81% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.50 |
| Price Target Difference | 950.81% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |